Drug and alcohol dependence最新文献

{"title":"Addiction research and national resilience: Protecting surveillance, treatment development, and integrated care","authors":"Julio C. Nunes, Joao P. De Aquino","doi":"10.1016/j.drugalcdep.2025.113002","DOIUrl":"10.1016/j.drugalcdep.2025.113002","url":null,"abstract":"","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113002"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized studies assessing the effect of flavor on pharmacokinetic and subjective parameters for dry and moist nicotine pouches","authors":"Mikael Staaf,&nbsp;Anna E. Masser ,&nbsp;Camilla Pramfalk ,&nbsp;Robert Pendrill,&nbsp;Sara Moses,&nbsp;Johan Lindholm,&nbsp;Tryggve Ljung","doi":"10.1016/j.drugalcdep.2026.113050","DOIUrl":"10.1016/j.drugalcdep.2026.113050","url":null,"abstract":"<div><h3>Background</h3><div>Nicotine pouches (NPs) have different formulations (e.g., dry or moist), and the vast majority are flavored. However, it is unclear if flavors exert any effect on nicotine pharmacology and subjective parameters.</div></div><div><h3>Methods</h3><div>Data from two, open-label, randomized, nine-way cross-over, single-dose administration, pharmacokinetic and subjective effects studies were analyzed, evaluating dry 6-mg and moist 9-mg NPs, respectively. The studies included unflavored and flavored varieties (flavor characteristics: traditional [tobacco], cooling, minty, fruit, beverage). All participants were adults who currently used snus and/or NPs daily (n = 38 for moist, n = 39 for dry).</div></div><div><h3>Results</h3><div>Maximum plasma concentrations (C_max) of nicotine were observed at NP removal at ~60<!--> <!-->min (T_max), with overlapping geometric least squares mean (GLSM) values for the dry and moist products (12.08–15.07<!--> <!-->ng/mL). The total nicotine exposure (calculated as area under the curve from time point 0 to infinity, AUC_inf) was 40.84–50.86<!--> <!-->h⁎ng/mL, with overlapping GLSM values for dry and moist varieties. Equivalence testing for AUC_inf and C_max between unflavored and flavored varieties showed equivalence for all varieties except two of the moist minty NPs. For subjective parameters, the effect of flavor was more pronounced for moist NPs, with participants rating the flavored varieties higher for satisfaction, product liking, and intent to use again.</div></div><div><h3>Conclusions</h3><div>For dry varieties, flavor had no effect on C_max and AUC_inf, but two moist varieties were different from moist unflavored. Flavor did not affect T_max for dry or moist NPs. Considerable variation in participant preferences suggest a need for diverse varieties and product types.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113050"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, tolerability, and drug-drug interactions of NYX-783 and oxycodone in persons using opioids recreationally: Preliminary results from a randomized, double-blind, placebo-controlled phase 1 study","authors":"Zachary M. Harvanek ,&nbsp;Marcella M. Mignosa ,&nbsp;Razi Kitaneh ,&nbsp;Henrique N.P. Oliva ,&nbsp;Anna Borelli ,&nbsp;Emalee Dauginikas ,&nbsp;Nia Fogelman ,&nbsp;Elcin Sakmar ,&nbsp;Jane Taylor ,&nbsp;Ralph DiLeone ,&nbsp;Rajita Sinha ,&nbsp;Gustavo A. Angarita","doi":"10.1016/j.drugalcdep.2026.113041","DOIUrl":"10.1016/j.drugalcdep.2026.113041","url":null,"abstract":"<div><h3>Background</h3><div>Novel treatments are needed for opioid use disorder (OUD). NYX-783, an NMDA positive allosteric modulator, affects synaptic plasticity and learning, key processes in. Although prior preclinical and studies in healthy humans have established its safety and tolerability, studies are needed in the context of opioid use.</div></div><div><h3>Methods</h3><div>Nine men who used opioids recreationally and passed a safety session were enrolled in inpatient study. Participants received single doses of NYX-783 (50<!--> <!-->mg, 150<!--> <!-->mg) and placebo and in combination with two oxycodone doses (15<!--> <!-->mg, 30<!--> <!-->mg), across six inpatient drug-drug interaction (DDI) sessions in a randomized, double-blind, crossover design. The primary endpoints included cardiovascular and respiratory safety, tolerability, and pharmacokinetics.</div></div><div><h3>Results</h3><div>No severe nor serious adverse events were reported and 85 % of adverse events were mild. NYX-783 reduced oxycodone’s calmative effects (p &lt; .0005). There was no effect of NYX-783 on feeling drug effect and high, nor wanting, liking, or disliking the drug. For the DDI sessions, there was no significant timepoint-by-NYX-783-by-oxycodone interaction for pulse, systolic &amp; diastolic blood pressure, temperature, pupillary dilation, subjective drug effects, nor electrocardiogram’s segments. There was a significant timepoint-by-NYX-by-oxycodone interaction for plasma NYX plasma levels (F = 3.19; DF = 8; p = 0.003) in which NYX levels were significantly higher when combined with 30<!--> <!-->mg of oxycodone vs. 15<!--> <!-->mg of oxycodone (p &lt; 0.0001).</div></div><div><h3>Conclusions</h3><div>NYX-783’s tolerability, safety, capacity to reduce oxycodone’s calmative effects and benign DDI profile offers support for future, larger (i.e., Phase 1B/2<!--> <!-->A) trials specifically targeting its safety and therapeutic potential in OUD.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113041"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of tobacco and other substance use with nicotine pouch awareness and use in US adolescents","authors":"Dae-Hee Han ,&nbsp;Tahsin Rahman ,&nbsp;Richard A. Miech ,&nbsp;Alyssa F. Harlow ,&nbsp;Hongying D. Dai ,&nbsp;Junhan Cho ,&nbsp;Steve Y. Sussman ,&nbsp;Louisiana M. Sanchez ,&nbsp;Leah R. Meza ,&nbsp;Adam M. Leventhal","doi":"10.1016/j.drugalcdep.2025.113016","DOIUrl":"10.1016/j.drugalcdep.2025.113016","url":null,"abstract":"<div><h3>Introduction</h3><div>Evidence on the association between tobacco/nicotine and other substance use (TOSU) and adolescent nicotine pouch (NP) awareness and use is lacking but vital for policy and prevention planning.</div></div><div><h3>Methods</h3><div>The sample was drawn from the 2023 Monitoring the Future study, a nationally representative survey of U.S. adolescents (8th, 10th, 12th graders). One-third of participants were randomly selected to complete questions on NP awareness and use (lifetime, past 12-month, past 12-month frequency) and past 30-day TOSU measures (yes/no). We estimated risk ratios (RRs) and incident rate ratios (IRRs) to examine the associations between TOSU and NP awareness and use.</div></div><div><h3>Results</h3><div>Overall (n = 6958; 53.4 % female), 35.4 % reported NP awareness, 2.5 % reported lifetime use, and 1.8 % reported past 12-month use. Past 30-day use of tobacco/nicotine products was each positively associated with NP awareness (RRs:1.42–1.70), lifetime (RRs:7.14–20.40), and past 12-month (RRs:5.84–22.44) use, with the strong associations for youth with vs. without smokeless tobacco use. Cannabis, alcohol, and other drug past 30-day use were each associated with NP awareness (RRs:1.49–1.68), lifetime (RRs:3.47–10.49), and past 12-month (RRs:4.70–15.70) use.</div></div><div><h3>Conclusions</h3><div>NP awareness and use prevalence were disproportionately high among adolescents with various forms of TOSU in 2023, especially smokeless tobacco. These findings suggest the importance of monitoring NP use among youth with TOSU while recognizing that awareness may also reflect broader marketing, product availability, or incidental exposure. Policy and prevention efforts should address NP use alongside TOSU with established health risks.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113016"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145914289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"β-Nicotyrine and e-cigarette abuse liability II: Behavioral economic demand and intracranial self-stimulation in rats","authors":"J.R. Smethells ,&nbsp;S. Wilde ,&nbsp;P. Muelken ,&nbsp;A.C. Harris ,&nbsp;M.G. LeSage","doi":"10.1016/j.drugalcdep.2026.113025","DOIUrl":"10.1016/j.drugalcdep.2026.113025","url":null,"abstract":"<div><h3>Background</h3><div>Given the prominence of electronic nicotine delivery systems (ENDS), understanding the product characteristics that underlie ENDS abuse liabilty is a public health research priority. β-Nicotyrine (β-Nic) is a uniquely prevalent constituent (up to 25 % of nicotine [Nic] levels) in ENDS aerosols that may contribute to ENDS abuse liability. Previously, we found clinically relevant concentration of β-Nic doubled the elimination half-life and prolong the interoceptive (discriminative stimulus) properties of Nic in rats, but that it had little or no psychoactive effects itself. The present study used i.v. self-administration (23 hrs/day) and intracranial self-stimulation (ICSS) paradigms to further evaluate if β-Nic alone has abuse liability or if it enhances the abuse liability of Nic.</div></div><div><h3>Methods</h3><div>We examined if β-Nic (&gt; 25 % of Nic levels) substitutes for Nic (0.03<!--> <!-->mg/kg/inf) during drug self-administration, and whether combinations of Nic and β-Nic alter the acquisition and behavioral economic demand of <em>i.v.</em> Nic. Reinforcement-enhancing and aversive effects of β-Nic alone or in combination with Nic were also evaluated using ICSS.</div></div><div><h3>Results</h3><div>Moderately high β-Nic doses (0.03 &amp; 0.10<!--> <!-->mg/kg/inf) increased demand for Nic (0.03<!--> <!-->mg/kg/inf). β-Nic alone did not maintain self-administration, affect ICSS, or influence the effects of Nic on ICSS.</div></div><div><h3>Conclusion</h3><div>β-Nic itself does not have abuse potential in either i.v. self-administration or ICSS models, but it does increase the reinforcing efficacy of self-administered Nic. As such, β-Nic may play a role in the abuse liability of ENDS, which has important treatment and regulatory implications.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113025"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociodemographic, behavioral, and geospatial factors associated with syringe services program use in San Francisco, California","authors":"Esther O. Chung ,&nbsp;Bradley Ray ,&nbsp;Jamie L. Humphrey ,&nbsp;Megan Lindstrom ,&nbsp;Cariné E. Megerian ,&nbsp;Barrot H. Lambdin ,&nbsp;Alex H. Kral","doi":"10.1016/j.drugalcdep.2026.113046","DOIUrl":"10.1016/j.drugalcdep.2026.113046","url":null,"abstract":"<div><h3>Background</h3><div>Syringe services programs (SSPs) are a cornerstone of preventing infectious disease and overdose for people who use drugs. Given efforts to achieve universal access, we examined factors associated with SSP use, including proximity.</div></div><div><h3>Methods</h3><div>We used cross-sectional data from 713 people who use drugs across San Francisco, California (September 2023-September 2024). We assessed proximity to an SSP by calculating the walking time between where participants slept the night before and nearest SSP location. We conducted multivariable negative binomial models to explore factors associated with SSP use and assess whether the association between proximity and SSP use was modified by race-ethnicity.</div></div><div><h3>Results</h3><div>Almost 80 % of participants used an SSP at least once in the past 3 months. Age, race-ethnicity, mode of use, and proximity to SSP were negatively associated with SSP use. Participants who only smoked used SSPs less often than those who used in other ways (adjusted rate ratio [aRR]=0.77, 95 % CI: 0.61–0.97), as well as those more than a 20-minute walk to an SSP (aRR=0.54, 95 % CI: 0.36–0.83). The effect size between walking time to SSP and SSP use was substantially larger for Black participants than non-Black (Black: aRR=0.38, 95 % CI: 0.15–0.60 vs. non-Black: aRR=0.72, 95 % CI: 0.40–1.31).</div></div><div><h3>Conclusions</h3><div>Geographic distance was a barrier to SSP use, especially for Black participants. SSPs may not reach people who only smoke drugs. SSPs should be added to areas with limited geographic access and include safer smoking supply distribution.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113046"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of acute adolescent stress on the acquisition and maintenance of intravenous oxycodone self-administration in male and female rats","authors":"Corinne A. Gallagher ,&nbsp;Daniel J. Chandler ,&nbsp;Daniel F. Manvich","doi":"10.1016/j.drugalcdep.2026.113030","DOIUrl":"10.1016/j.drugalcdep.2026.113030","url":null,"abstract":"<div><h3>Background</h3><div>The persistent threat of the opioid epidemic warrants investigation into risk factors that predispose individuals to opioid use disorder (OUD). Adolescent stress has been linked to enhanced risk for OUD in humans, however, attempts to model this preclinically have yielded mixed results. Additionally, few studies have explored whether adolescent stress modulates the reinforcing effects of prescription opioids. Here we investigate the impact of acute adolescent stress on oxycodone self-administration in male and female rats.</div></div><div><h3>Methods</h3><div>Adolescent male and female rats underwent acute restraint stress during concurrent exposure to predator odor, or control handling. Approximately one week later, subjects were allowed to acquire IV oxycodone self-administration (0.03<!--> <!-->mg/kg/inf) over 10 sessions (2<!--> <!-->h/day) under a fixed-ratio 1 (FR1) schedule of reinforcement. Following three additional FR1 sessions and seven sessions under FR3, rats underwent two progressive-ratio tests (0.03<!--> <!-->mg/kg/inf and 0.06<!--> <!-->mg/kg/inf, respectively). Separate groups of adolescent rats underwent similar experimental manipulations but were trained on sucrose reinforcement.</div></div><div><h3>Results</h3><div>Adolescent stress did not affect the rate of acquisition of IV oxycodone self-administration. However, oxycodone self-administration escalated during post-acquisition FR1 sessions and remained elevated during FR3 sessions in stressed rats as compared to unstressed controls. Adolescent stress exposure did not affect responding during progressive-ratio tests, nor did it affect any measure of sucrose pellet reinforcement.</div></div><div><h3>Conclusions</h3><div>The present results are the first to demonstrate adolescent stress-induced enhancement of oxycodone reinforcement in rats and provide a preclinical model for investigating the neurobiological mechanisms by which adolescent stress increases vulnerability for prescription opioid misuse.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113030"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145923355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retreatment with nicotine replacement therapy: Predictors of re-enrolment in a cohort of people who smoke seeking treatment in ambulatory settings","authors":"Xue Man ,&nbsp;Peter Selby ,&nbsp;Laurie Zawertailo ,&nbsp;Scott Veldhuizen","doi":"10.1016/j.drugalcdep.2026.113056","DOIUrl":"10.1016/j.drugalcdep.2026.113056","url":null,"abstract":"<div><h3>Background</h3><div>People who re-enrol in smoking cessation treatment repeatedly may benefit from more intensive or alternative interventions. We aimed to measure differences across participants in propensity to re-enrol in a large treatment program, to describe re-enrolment patterns, and to examine specific participant characteristics that predict re-enrolment.</div></div><div><h3>Methods</h3><div>We analyzed 172,050 enrolments into the Ontario-wide Smoking Treatment for Ontario Patients (STOP) program between 2014 and 2023. STOP provides up to 26 weeks of nicotine replacement therapy (NRT) and allows re-enrolment after one year. We used probabilistic deduplication to identify 128,481 unique individuals. To analyze re-enrolment, we fit a mixed-effects Cox proportional hazards survival model for recurrent events, with demographic, clinical, and contextual variables included as fixed effects.</div></div><div><h3>Results</h3><div>Of all enrolments, 25.3 % (43,569) were repeat entries. Participant-level variance was very high (σ2 =1.66, median hazard ratio = 3.4), indicating large residual individual-level differences in propensity to re-enrol. The strongest predictors of reenrolment were time to first cigarette after waking (p &lt; 0.001), lifetime quit attempts (p &lt; 0.001), type of NRT provided (p &lt; 0.001) and total visits in previous enrolment (HR 1.10, 95 % CI 1.10–1.11), clinic type (p &lt; 0.001), schizophrenia (HR 1.51, 95 % CI 1.41–1.60), and enrolment during the COVID-19 era (HR 1.31, 95 % CI 1.20–1.44).</div></div><div><h3>Conclusion</h3><div>Propensity to re-enrol varied markedly across individuals, implying that there is a subgroup of treatment-seeking people who are less likely to achieve longterm abstinence. Alternative interventions or long-term nicotine replacement may be justified for these individuals.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113056"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of metabolic syndrome components on fibrosis severity and mortality in alcohol-related liver disease","authors":"Kodjo Kunale Abassa ,&nbsp;Hongsheng Yu ,&nbsp;Shuyan Tan ,&nbsp;Mingkai Li ,&nbsp;Zhenwei Zhong ,&nbsp;Haoxiong Zhou ,&nbsp;Yunwei Guo","doi":"10.1016/j.drugalcdep.2026.113027","DOIUrl":"10.1016/j.drugalcdep.2026.113027","url":null,"abstract":"<div><h3>Background/ Aim</h3><div>The prognosis of concomitant chronic liver disease and metabolic syndrome (MetS) has been established. However, data on the impact of individual MetS components on mortality in patients with alcohol-related liver cirrhosis (ALC) remain scarce.</div></div><div><h3>Methods</h3><div>A cross-sectional cohort of 120 patients with alcohol-related liver disease (ArLD) and a longitudinal cohort of 789 patients with ALC were retrospectively enrolled. Patients were categorized into three groups based on the number of MetS components present: Group 1 included patients with no MetS components; Group 2 included those with 1 or 2 components; and Group 3 included patients with ≥ 3 components. Kaplan–Meier and regression analyses were performed to assess the severity of fibrosis in patients with ArLD and to compare mortality outcomes among those with ALC.</div></div><div><h3>Results</h3><div>Patients with ArLD in group 3 had the highest odds of significant fibrosis [adjusted OR = 2.80 (95 % CI: 1.01–7.76)] and advanced fibrosis [adjusted OR = 17.1 (95 % CI: 3.58–81.9)]. Elevated glucose levels were the only independent factor associated with both significant and advanced fibrosis. Furthermore, the presence of ≥ 3 MetS components predicted higher all-cause mortality (adjusted HR = 5.91, 95 % CI: 2.98–11.75) and liver-related mortality (adjusted HR = 4.73, 95 % CI: 2.05–10.94) in patients with ALC, with glucose and triglycerides levels emerging as the most significant independent risk factors. The presence of diabetes further exacerbated mortality risk in patients with ≥ 3 MetS components.</div></div><div><h3>Conclusions</h3><div>MetS, particularly abnormal fasting glucose, exacerbated liver fibrosis and significantly worsened mortality in patients with ArLD.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113027"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and clinical predictors of a virtual based combined cognitive behavioral and motivational enhancement group therapy for adults with cannabis use disorder","authors":"Dhvani D. Mehta ,&nbsp;Rachel Goud ,&nbsp;Marcos Sanches ,&nbsp;Leslie Buckley ,&nbsp;Matthew E. Sloan ,&nbsp;Julianne Vandervoort ,&nbsp;Bernard Le Foll ,&nbsp;Narges Beyraghi ,&nbsp;Pamela Kaduri ,&nbsp;Laurie Zawertailo ,&nbsp;Peter Selby ,&nbsp;Victor M. Tang","doi":"10.1016/j.drugalcdep.2026.113048","DOIUrl":"10.1016/j.drugalcdep.2026.113048","url":null,"abstract":"<div><h3>Background</h3><div>Cannabis use has increased in recent years, while perceptions of harm have declined. Cognitive behavioural therapy (CBT), motivational enhancement therapy (MET), and their combinations (CBT-MET) are evidence-based interventions for CUD, though their effectiveness when delivered virtually is underexplored. This study evaluated the clinical efficacy of a virtual 12-week group-based CBT-MET program in individuals with CUD and examined baseline predictors of treatment response.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on 116 adults enrolled in a virtual group-based CBT-MET program between 2020 and 2023. Participants completed weekly self-report assessments of cannabis use and biweekly assessments of depression (PHQ-9) and anxiety (GAD-7). Cannabis craving (MCQ) and a measure of problematic cannabis use (CUDIT) were assessed at baseline and post-treatment. Wilcoxon signed-rank tests evaluated changes among completers (≥ 75 % attendance), and linear mixed models identified baseline predictors of change over time.</div></div><div><h3>Results</h3><div>Of the 116 participants, 79 (68 %) completed the program, indicating high retention. Among completers, significant reductions were observed in cannabis use frequency (p &lt; 0.01), quantity (p &lt; 0.01), craving (p &lt; 0.01), depression (p &lt; 0.01), and anxiety (p = 0.02). Higher baseline cannabis use predicted greater reductions in cannabis frequency and quantity, while higher self-efficacy predicted lower cannabis use frequency across treatment. Individuals with co-occurring substance use disorders other than tobacco demonstrated smaller reductions in cannabis quantity.</div></div><div><h3>Conclusion</h3><div>Virtual CBT-MET was feasible and led to significant reductions in cannabis use and psychiatric symptoms among individuals with CUD. Baseline cannabis use patterns and self-efficacy were key predictors of reduction in cannabis use, highlighting the need for personalized approaches in future interventions.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113048"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145974309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}